Synthesis of influenza virus mRNA is primed by capped and methylated (cap 1, m7GpppXm) RNAs which the virus derives by endonucleolytic cleavage from RNA polymerase II transcripts in host cells. The conserved nature of the endonucleolytic processing provides a unique target for the development of antiviral agents for influenza viruses. A series of 4-substituted 2,4-dioxobutanoic acid compounds has been identified as selective inhibitors of this activity in both influenza A and B viruses. These inhibitors exhibited 50%o inhibitory concentrations in the range of 0.2 to 29.0 ,uM for cap-dependent influenza virus transcription and had no effect on the activity of other viral and cellular polymerases when tested at 100-to 500-fold higher concentrations. The compounds did not inhibit the initiation or elongation of influenza virus mRNA synthesis but specifically inhibited the cleavage of capped RNAs by the influenza virus endonuclease and were not inhibitory to the activities of other nucleases. Additionally, the compounds specifically inhibited replication of influenza A and B viruses in cell culture with potencies comparable to the 50% inhibitory concentrations obtained for transcription.
Influenza A and B viruses cause an acute respiratory infection in humans which can progress to severe pulmonary infection, resulting in considerable mortality and morbidity in elderly and other high-risk individuals. Because currently available vaccines are not completely protective against influenza virus infection, there is interest in the development of anti-influenza virus therapeutic agents. Presently, the only licensed antiviral agents for influenza virus are amantadine and rimantadine, which are of limited utility because of their ineffectiveness against influenza B viruses and because they generate transmissible resistant mutants (14) .
Influenza virus is a negative-strand RNA virus with a segmented genome. Synthesis of influenza virus mRNA occurs in the nucleus of infected host cells and is catalyzed by a virally encoded polymerase complex consisting of three polymerase proteins, PB1, PB2, and PA (21) . Influenza virus transcription is initiated by a novel mechanism in which capped and methylated RNAs, acquired from RNA polymerase II transcripts of host cells, are used to prime the synthesis of mRNA. The primers are derived by a virion-encoded endonuclease which cleaves the capped cellular RNAs 13 nucleotides (nt) from the 5' end, yielding a 13-nt capped RNA with a 3' OH terminus. The nucleotide complementary to the penultimate base in the 3' end of the template viral RNA is then added onto the 3' end of the primer, and the elongation of mRNA chains then proceeds (28) .
Primary transcription of influenza virus is an attractive antiviral target for several reasons. The transcriptase is essential for virus replication in mammalian cells (27) . It is highly conserved in influenza A and B viruses (40) , and cap-depen-dent cleavage appears to be a unique property of influenza virus, having no known cellular counterpart. Only Bunyaviruses, also negative-strand, segmented RNA viruses, have been shown to possess a similar cap-dependent endonuclease activity. Bunyavirus transcription differs, however, in that Bunyavirus mRNAs are synthesized in the cytoplasm, and therefore, transcription is primed with a stable pool of capped RNA transcripts (31) .
Although our understanding of the function and interaction of the polymerase proteins in the transcriptase complex is limited, the activities associated with the PB1 and PB2 proteins have been described on the basis of genetic and biochemical studies. Polymerase protein PB1 is required for the incorporation of the first nucleotide onto the capped RNA primers and is also involved in the elongation of mRNA chains (5, 17, 29) . The PB2 protein binds to the capped primer and may also be responsible for the endonuclease activity (5, 25, 37) . Several polymerase motifs have been identified in the PB1 genes of influenza A and B viruses, and these motifs are conserved among RNA-dependent polymerases of viral and retroid origin, including two motifs which are highly conserved among DNA and RNA polymerases of procaryotes and eucaryotes (9, 19) . It has also been suggested that homology exists between the primary sequence of eucaryotic cap-binding proteins and the influenza virus cap binding protein, PB2; however, the degree of conservation is far less extensive (8) . Therefore, although the homology shared by PB1 and other polymerases indicates that elongation of mRNA may not be an activity specific to influenza virus, the endonucleolytic processing of capped RNA primers appears to be a unique viral function.
Cap-dependent transcription of influenza virus can be performed in vitro (4) . This is a multistep process that includes the binding and endonucleolytic cleavage of capped RNA primers, the initiation of RNA polymerization, and the subsequent MATERIALS AND METHODS Enzymes and reagents. Guanylyltransferase was purchased from Bethesda Research Laboratories (Gaithersburg, Md.), S-adenosyl methionine (SAM) was from Boehringer Mannheim (Indianapolis, Ind.), RNases U2 and Ti were from Pharmacia (Piscataway, N.J.), and bovine pancreatic A RNase was from Sigma (St. Louis, Mo.). Nucleoside-2'-methyltransferase was purified from vaccinia virus virions which were kindly supplied by R. Bablanian (Health Science Center, State University of New York, Brooklyn) by the method of Barbosa and Moss (2) .
Chemical synthesis of influenza virus transcriptase inhibitors. The dioxobutanoic acids were all prepared from the corresponding methyl ketones by reaction with dimethyl oxalate and sodium hydride and then hydrolysis of the intermediate methyl dioxobutanoic ester (11, 38) . Compounds 4 to 8 (Tables 1 and 2) were prepared from commercially available methyl ketones by the method described above. The synthesis of compound 3 (L-735,882; 4-[N-benzyl-3-(4-chlorobenzyl)piperidin-3-yl]-2,4-dioxobutanoic acid) was accomplished by treatment of ethyl-N-(tert-butyloxycarbonyl)-3-piperidine carboxylate with lithium bis(trimethylsilyl amide) in tetrahydrofuran and then 4-chlorobenzyl chloride, which gave rise to ethyl-3-(4-chlorobenzyl)-N-(tert-butyloxycarbonyl)-3-piperidine carboxylate. Hydrolysis of the ester (10 N NaOH) gave the carboxylic acid, which was converted to a methyl ketone by the following sequence: (i) acid chloride formation with oxalyl chloride, (ii) N,O-dimethylhydroxamide formation with N,Odimethylhydroxyl amine, and (iii) reaction with methylmagnesium bromide at 60°C. The tert-butyloxycarbonyl protecting group was removed with gaseous hydrochloric acid to give the piperidine amine, 3-acetyl-3-(4-chlorobenzyl), which was then alkylated with benzyl chloride to form 3-acetyl-N-benzyl-3-(4-chlorobenzyl)piperidine. Treatment of this methyl ketone with dimethyl oxalate and sodium hydride produced the corresponding methyl dioxobutanoic ester, which was converted to compound 3 by acid hydrolysis. Compound 1 was prepared by a similar route except that the 3-acetyl-3-(4-chlorobenzyl)piperidine was sulfonylated with phenylmethylsulfonyl chloride before the oxalation sequence. Compound (24) .
In vitro influenza virus transcriptase assays. In vitro influenza virus transcriptase assays with detergent-disrupted virions or purified polymerase cores were performed by a modification of a previously described procedure (4 Substitutions were made in the lipophilic portion of the molecule, and it was found that placement of alkyl groups proximal to the side chain resulted in improved potency. Many dioxobutanoic acid compounds with saturated cycloalkyl substitutions were synthesized, and in particular, a class of piperidine substituted 2,4-dioxobutanoic acids was found to be the most potent; examples of these compounds appear in Table 1 (compounds 1 to 3; IC50s, 0.2 to 1.1 ,uM). Further structural modification of the piperidine nitrogen by benzyl and alkyl substitutions yielded compounds which had antiviral activity in cell culture. Two of the more active of these were compounds 2 and 3 (L-735,882).
It should be noted that compound 4 and various mono-and diacidic molecules with lipophilic substituents have previously been described to be competitive inhibitors of porcine glycolate oxidase (GAO) (30, 38) . However, several reported inhibitors of GAO had no effect on influenza virus transcription when the inhibitors were tested at up to 100-fold above the GAO IC50s (data not shown). The alkyl-substituted dioxobutanoic acids (compounds 1 to 3) were not tested in a GAO assay.
Specificities of transcriptase inhibitors. Several of the most potent compounds developed in the dioxobutanoic acid series (see above) were chosen for characterization, including compound 3, L-735,882, a benzyl-substituted piperidine, which exhibited antiviral activity in cell culture (see below) and thus is described further. The inhibitory profile obtained for L-735,882 against several enzymes with similar activities (which was analogous to the inhibitory specificities elicited by all other derivatives of the series tested in the assays; data not shown) demonstrated that these inhibitors were highly selective for the influenza yirus transcriptase. The compound was specific for the influenza virus polymerase and had no effect in other polymerase assays including VSV transcription, human immunodeficiency virus (HIV) reverse transcriptase, T7 phage, HeLa cell RNA polymerase II, and HeLa cell DNA polymerase ao when tested up to 100-to 500-fold above the IC50 (Table 3) . Compound L-735,882 specifically inhibited cap-dependent influenza virus transcription and did not inhibit transcription when primed cap independently with the dinucleotide ApG at concentrations of compound up to 1,000-fold greater than the IC50 for ALMV-primed transcription (Table 3) . Furthermore, L-735,882 showed activity in a cap-dependent primed transcription comparable to those against several other influenza A and B virus polymerases (Table 4) . Additionally, inhibition of transcription was similar with either detergent-disrupted virions or purified polymerase cores as the enzyme source (data not shown).
Inhibition of influenza virus cleavage. The observation that the 4-substituted dioxobutanoic acids inhibited cap-dependent but not cap-independent priming of influenza virus transcription raised the possibility that these compounds affected the endonucleolytic processing of capped primer substrate. Therefore, inhibitor L-735,882 was tested in a direct influenza virus cleavage assay by using an ALMV RNA substrate radiolabeled by incorporation of [32P]GTP into the 5' cap. The compound inhibited cleavage of the 32P-end-labeled ALMV ( Fig. 1 and Table 3 ) with an IC50 of 1.8 ,uM, which was comparable to the IC50 obtained in the transcription assay (1.1 ,uM). The IC50s for transcription and cleavage were also similar to those of other derivatives of this series. The inhibitor L-735,882 had no effect upon other nucleases including HIV RNase H, RNase U2 (Ustilago sphaerogena), RNase Ti (Aspergillus oryzae), bovine pancreatic RNase A, and EcoRI restriction endonuclease (Table 3) when tested at concentrations 100-to 500-fold greater than the IC50 for cleavage. Specific inhibition of the influenza virus endonuclease was also demonstrated by other derivatives of the series in these assays (data not shown).
Uncoupling of cleavage and elongation. Compound L-735,882 was also tested in a transcriptase assay in which endonuclease and elongation reactions were uncoupled. Capped RNA substrates of 13, 22, and 70 nt derived from the sequence of the 5' end of the ALMV RNA were synthesized by T7 runoff transcription by the duplex promoter method of Milligan et al. (24) . The 13-nt substrate represented the authentic endonucleolytic cleavage product of the 880-nt ALMV substrate and was not cleaved by influenza virus endonuclease when radiolabeled at the 5' end, while the two substrates of 22 and 70 nt contained the cleavage site present in ALMV RNA and were cleaved by influenza virus endonuclease. These synthetic RNAs were used as primers in influenza virus transcription. Only transcription reactions primed with the 22-and 70-nt substrates, which undergo endonucleolytic processing, were inhibited by L-735,882, with IC50s similar to those obtained for transcription primed with the 880-nt ALMV substrate (Fig. 2) . Furthermore, L-735,882 had no effect on the addition of radiolabeled GTP onto the 3' OH terminus of the 13-nt primer (showing that the compounds did not inhibit the initiation of elongation), but did inhibit the addition of [32P]GTP onto the 22-, 70-, and 880-nt capped substrates which undergo endonucleolytic processing (data not shown). Similar activity profiles in these reactions were demonstrated for several derivatives in the series. In contrast, several lignin and polyphenolic compounds (identified as nonspecific influenza virus transcriptase inhibitors in a random screening effort) and the PP1 analog phosphonoformic acid (PFA) inhibited transcription primed with all four capped RNA substrates but had no effect on cleavage (unpublished data).
Substrate competition. Compound L-735,882 was not competitive with respect to the cap 1 substrate ALMV RNA (880 nt), as shown in Fig. 3 . Increasing amounts of the substrate (up to 1 mM) did not alter the degree of inhibition caused by L-735,882. The Km of the substrate was relatively unchanged from 6.1 nM for the uninhibited reaction to 9.7 nM for the inhibited reaction, while Vm. was substantially decreased from the inhibition of transcription by 250 puM cap dinucleotide m7GpppGm, a known inhibitor of cap-dependent transcription (20) , in which the observed inhibition was overcome by increasing amounts of the ALMV substrate. At high concentrations of the ALMV RNA substrate, the reaction inhibited by the cap dinucleotide reached a Vm, of 2.4 pmol of product in 60 min, and the Km of the substrate was increased to 95 nM. Therefore, unlike the cap 1 analog, L-735,882 was not competitive with capped substrate. Related dioxobutanoic acid compounds were also tested in mammalian and viral cap recognition assays and were not inhibitory to in vitro translation of mRNA in rabbit reticulocytes and vaccinia virus methylation of capped RNA when tested at concentrations as high as 1.5 mM. Additionally, the compounds were not competitive with nucleoside triphosphate substrates in transcription (data not shown).
Effect the compounds were evaluated in a cell culture assay for influenza viruses in which the effects of the compounds on a single cycle of replication were quantitated by measurement of viral protein synthesis. As shown in Fig. 4 , L-735,882 inhibited the synthesis of 35S-radiolabeled influenza A and B virus proteins by 50% at concentrations of 6 and 2 ,uM, respectively, but had no effect on the synthesis of LACV (a Bunyavirus) proteins when it was tested up to 30 puM. Additionally, the compound had no effect on the replication of VSV, NDV, or MEV when it was tested in a similar assay. (Fig. 5) . Noti attained in the plaque reduction assay (50 pu1 potent than that attained in the virus yield demonstrating the effect of the compound reduction. The antiviral activity was observed i cytoxicity, because testing of compound L-73' trations of up to 100 ,iM had no effect on the MDCK cells in growth medium when growth by the MTS colorimetric method during 24-periods (Fig. 5) . At concentrations of up t compound likewise had no effect on the grow cells in the virus yield assay measured durin period of the assay.
DISCUSSION
The transcriptase of influenza virus is a pot the development of antiviral agents because for an essential and highly conserved catalytic virus. In this report we described a novel class inhibitors, 4 (33) . Anti-influenza virus activity has also been observed in vivo for the nucleoside analogs 2'-deoxy-2'-fluororibosides, whose modes of action are possibly directed at primary and secondary transcription. However, these compounds also inhibit other viral and bacterial polymerase as well (35) . inhibitors had no effect in reactions primed with the 13-nt substrate; only reactions primed with capped substrates which required endonucleolytic processing prior to nucleotide addition were inhibited. In contrast, elongation inhibitors such as lignins, polyphenolic compounds, and PFA inhibited influenza tential target for virus transcription primed with both the 13-nt substrate and it is responsible the capped substrates which undergo endonucleolytic processfunction of the ing, but they had no effect on cleavage (unpublished data). of transcriptase Thus, the dioxobutanoic acid compounds are a class of trands, which specifscriptase inhibitors which differ mechanistically from inhibitors transcriptase.
of elongation, perhaps by interaction with a form of the f influenza virus polymerase complex involved in cap-dependent initiation that In addition to the inhibitory activities observed for the dioxobutanoic acids in the in vitro enzyme assays, benzylsubstituted compounds inhibited the replication of both influenza A and B viruses in cell culture in the absence of apparent cytotoxic effects. The antiviral activity was specific for influenza viruses because the compounds had no effect on the replication of several other viruses including LACV, a Bunyavirus, a finding which correlated with the biochemical selectivities of the dioxobutanoic acids. Furthermore, the inhibitors were active in both single and multicycle replication assays, demonstrating the effectiveness of these compounds not only on an initial cycle of influenza virus replication but on subsequent rounds as well.
In summary, this is the first report of a specific class of inhibitors for the in vitro transcriptase and replicative activities of influenza A and B viruses. The mode of action of these compounds, inhibition of the cap-dependent endonuclease activity of the viral polymerase complex, differs from the previously reported activities of transcriptase inhibitors, which inhibited the elongation of mRNA by influenza virus polymerases and other polymerases. The selectivities of the inhibitors described here demonstrate the unique and conserved nature of the endonuclease of influenza virus transcriptase, thereby supporting the potential exploitation of this viral enzyme as a target of intervention in the replication of influenza viruses. Although additional studies are required to define precisely the mechanistic role of these inhibitors in endonuclease inhibition, the dioxobutanoic acids will be useful in further probing the biochemical and biological properties of this antiviral target.
